$7.65 -0.10 (-1.29%)
Kazia Therapeutics Limited American Depositary Shares (KZIA)
Company News
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner
Kazia Therapeutics plans to request an FDA meeting to discuss overall survival data for paxalisib, a potential treatment for glioblastoma, aiming to pursue conditional approval under the FDA's Project FrontRunner initiative.
Leptomeningeal Metastases Market to Exhibit Growth at a Paltry CAGR of 1.9% During the Forecast Period (2025–2034) | DelveInsight
The leptomeningeal metastases market is projected to grow slowly due to rising cancer incidence and increasing central nervous system complications. Several emerging therapies like REYOBIQ and Paxalisib are expected to drive market development in the coming years.
Beat the Market the Zacks Way: Kazia Therapeutics, Uber, Medtronic in Focus
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.